136 related articles for article (PubMed ID: 17061285)
1. HIV-1 encephalopathy among perinatally infected children: Neuropathogenesis and response to highly active antiretroviral therapy.
Mitchell CD
Ment Retard Dev Disabil Res Rev; 2006; 12(3):216-22. PubMed ID: 17061285
[TBL] [Abstract][Full Text] [Related]
2. Neurocognitive outcomes in pediatric HIV.
Willen EJ
Ment Retard Dev Disabil Res Rev; 2006; 12(3):223-8. PubMed ID: 17061290
[TBL] [Abstract][Full Text] [Related]
3. Neurodevelopmental outcomes in children with HIV infection under 3 years of age.
Foster CJ; Biggs RL; Melvin D; Walters MD; Tudor-Williams G; Lyall EG
Dev Med Child Neurol; 2006 Aug; 48(8):677-82. PubMed ID: 16836781
[TBL] [Abstract][Full Text] [Related]
4. Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active anti-retroviral therapy (HAART).
Chiriboga CA; Fleishman S; Champion S; Gaye-Robinson L; Abrams EJ
J Pediatr; 2005 Mar; 146(3):402-7. PubMed ID: 15756229
[TBL] [Abstract][Full Text] [Related]
5. [Nervous system manifestations in HIV infected children].
Funk M; Joseph-Steiner J; Hernaiz-Driever P; Mentzer D; Göhlich-Ratmann G; Bollinger M; Kreuz W; Kornhuber B; Jacobi G
Klin Padiatr; 1996; 208(5):299-303. PubMed ID: 8992098
[TBL] [Abstract][Full Text] [Related]
6. [Cerebral symptoms in pre- or perinatally HIV-infected children].
Koch S; Vocks-Hauck M; Henning S; Grosch-Wörner I
Dtsch Med Wochenschr; 1993 Apr; 118(13):445-50. PubMed ID: 7682171
[TBL] [Abstract][Full Text] [Related]
7. Long-term effectiveness of highly active antiretroviral therapy (HAART) in perinatally HIV-infected children in Denmark.
Bracher L; Valerius NH; Rosenfeldt V; Herlin T; Fisker N; Nielsen H; Obel N
Scand J Infect Dis; 2007; 39(9):799-804. PubMed ID: 17701719
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
Tonwe-Gold B; Ekouevi DK; Viho I; Amani-Bosse C; Toure S; Coffie PA; Rouet F; Becquet R; Leroy V; El-Sadr WM; Abrams EJ; Dabis F
PLoS Med; 2007 Aug; 4(8):e257. PubMed ID: 17713983
[TBL] [Abstract][Full Text] [Related]
9. Initiating highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children in Europe and the United States: comparing clinical practice to guidelines and literature evidence.
Verweel G; Saavedra-Lozano J; van Rossum AM; Ramilo O; de Groot R
Pediatr Infect Dis J; 2006 Nov; 25(11):987-94. PubMed ID: 17072119
[TBL] [Abstract][Full Text] [Related]
10. Morbidity in HIV-1-Infected children treated or not treated with highly active antiretroviral therapy (HAART), Abidjan, Cote d'Ivoire, 2000-04.
Walenda C; Kouakoussui A; Rouet F; Wemin L; Anaky MF; Msellati P
J Trop Pediatr; 2009 Jun; 55(3):170-6. PubMed ID: 19066169
[TBL] [Abstract][Full Text] [Related]
11. Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART.
Chiappini E; Galli L; Tovo PA; Gabiano C; Lisi C; Gattinara GC; Esposito S; Viganò A; Giaquinto C; Rosso R; Guarino A; de Martino M
AIDS; 2007 Jul; 21(12):1607-15. PubMed ID: 17630556
[TBL] [Abstract][Full Text] [Related]
12. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
13. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
Larrú B; Resino S; Bellón JM; de José MI; Fortuny C; Navarro ML; Gurbindo MD; Ramos JT; Soler Palacín P; Léon JA; Asensi M; Mellado MJ; Muñoz-Fernández MA
J Antimicrob Chemother; 2008 Jan; 61(1):183-90. PubMed ID: 18025025
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of HIV infection from the neurologic viewpoint. Therapy must reach the brain].
von Giesen HJ; Köller H; Arendt G
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():46-50. PubMed ID: 12043074
[TBL] [Abstract][Full Text] [Related]
15. [Course and treatment of progressive subacute encephalopathy caused by human immunodeficiency virus in children. The value of Botulinum toxin].
Noguera-Julian A; Pérez-Dueñas B; Fortuny-Guasch C; López-Casas J; Póo P
Rev Neurol; 2004 Feb 1-15; 38(3):239-43. PubMed ID: 14963851
[TBL] [Abstract][Full Text] [Related]
16. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
Taha TE; Kumwenda J; Cole SR; Hoover DR; Kafulafula G; Fowler MG; Thigpen MC; Li Q; Kumwenda NI; Mofenson L
J Infect Dis; 2009 Nov; 200(10):1490-7. PubMed ID: 19832114
[TBL] [Abstract][Full Text] [Related]
17. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV.
Palombi L; Marazzi MC; Voetberg A; Magid NA
AIDS; 2007 Jul; 21 Suppl 4():S65-71. PubMed ID: 17620755
[TBL] [Abstract][Full Text] [Related]
18. Influence of highly active antiretroviral treatment (HAART) on risk factors for vertical HIV transmission.
Garcia-Tejedor A; Maiques V; Perales A; Lopez-Aldeguer J
Acta Obstet Gynecol Scand; 2009; 88(8):882-7. PubMed ID: 19557554
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
Ekouevi DK; Coffie PA; Becquet R; Tonwe-Gold B; Horo A; Thiebaut R; Leroy V; Blanche S; Dabis F; Abrams EJ
AIDS; 2008 Sep; 22(14):1815-20. PubMed ID: 18753864
[TBL] [Abstract][Full Text] [Related]
20. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
